New combo therapy targets hard-to-treat lung cancer mutation
NCT ID NCT07543172
First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 2 times
Summary
This study tests whether adding a cancer vaccine (CIMAVAX-EGF) to standard targeted drugs (sotorasib or adagrasib) can help control advanced lung cancer with a KRAS G12C mutation. About 29 adults with stage III or IV non-small cell lung cancer will receive the combination. The goal is to see if it delays cancer growth longer than the drugs alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Facing the fear: a new program aims to ease anxiety in advanced cancer
- Can a Chemo-Immunotherapy duo outsmart tough lung cancer?
- Could a simple assessment help older lung cancer patients tolerate chemo better?
- Could a muscle relaxant help fight lung cancer? scientists test papaverine with standard therapy
- Wheat germ supplement studied for immune boost in advanced cancer
- New imaging agent may help doctors see which lung tumors are still growing during immunotherapy